Market Overview:
The global post-traumatic stress disorder therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of PTSD, rising awareness about PTSD and its treatment options, and the launch of novel therapies for PTSD. However, patent expirations of key products and stringent regulatory requirements are some factors that could hamper the growth of this market in the coming years. The global post-traumatic stress disorder therapeutics market can be segmented on the basis of type into antidepressants and anxiolytics. On the basis of application, it can be segmented into hospital pharmacies, retail pharmacies, and other applications such as clinics or individual practitioners’ offices. Geographically, it can be divided into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . North America is expected to dominate this market during the forecast period owing to high prevalence rates for PTSD in countries such as U.S., Canada ,and Mexico .
 Therapeutics Industry Outlook.svg)
Product Definition:
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur after someone experiences or witnesses a traumatic event. Symptoms may include flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the event. PTSD can make it difficult to function normally in daily life. Treatment may include medications, therapy, or both.
Antidepressants:
Antidepressants are the drugs that cure depression. They can be used to treat symptoms of depression as well as the root cause of the disorder. The global antidepressants market is expected to witness significant growth over the forecast period owing to factors such as growing awareness about mental health disorders and increasing prevalence of major depressive disorders (MDD) across all age groups.
Anxiolytics:
Anxiolytics is a class of drug that reduces anxiety. The most commonly used anxiolytic drugs are benzodiazepines, which are widely prescribed for the treatment of panic disorders and anxiety associated with Generalized Anxiety Disorder (GAD). Anxiolytic’s market is driven by factors such as growing prevalence of mental health disorders coupled with increasing awareness about their treatments.
Application Insights:
On the basis of application, the global PTSD therapeutics market is segmented into hospital, pharmacy and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to factors such as high prevalence of trauma cases and increasing awareness among patients regarding treatment. Moreover, an increase in government initiatives for improving healthcare infrastructure across developing countries is expected to boost product demand over the forecast period.
The other application segment includes independent living centers, residential care facilities and specialty clinics that provide PTSD therapy services. Growing awareness about mental health issues coupled with rising number of traumatic experiences are anticipated to drive growth over the forecast period. Increasing availability of mental health professionals at reduced costs due to a decline in their standard salaries has also fueled growth within this segment during recent years (2016-2020).
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in awareness about PTSD and its treatment options, increasing government initiatives, and availability of effective therapies. Moreover, presence of key players such as Pfizer Inc.; Ortho-McNeil Pharmaceutical; Janssen Pharmaceutica; Allergan Plc.; and sanofi are also contributing towards growth of this regional market.
Asia Pacific is expected to witness fastest growth during the forecast period due to rising incidence rates of trauma & PTS disorders coupled with growing number of patients seeking treatment for these conditions. In addition, increasing prevalence rate for chronic diseases such as cardiovascular disease (CVD) has led to an increase in CVD-related traumatic experiences which further increases the demand for post traumatic stress disorder therapeutics in Asia Pacific region. Presence or expansion plans by major companies will also contribute towards regional growth over the forecast period (2018 - 2030).
Growth Factors:
- Increasing awareness about PTSD and its treatment options among people
- Growing number of research studies on PTSD that are helping to identify new treatment approaches
- increasing number of veterans returning from wars with PTSD, which is driving the demand for better therapies for the disorder
- Development of novel drugs and therapies for treating PTSD
- Increased focus on mental health by governments and other funding organizations
Scope Of The Report
Report Attributes
Report Details
Report Title
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Research Report
By Type
Antidepressants, Anxiolytics
By Application
Hospital, Pharmacy, Other
By Companies
GlaxoSmithKline, Pfizer, Eli Lilly, H. Lundbeck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Report Segments:
The global Post-Traumatic Stress Disorder (PTSD) Therapeutics market is segmented on the basis of:
Types
Antidepressants, Anxiolytics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- H. Lundbeck
 Therapeutics Market Overview.svg)
Highlights of The Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antidepressants
- Anxiolytics
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Post-traumatic stress disorder (PTSD) is a mental health condition that can develop after exposure to a traumatic event, such as military combat, sexual assault, or natural disaster. PTSD can cause intense fear and anxiety that lasts for months or years after the original event. People with PTSD may have difficulty sleeping, concentrating, and functioning in everyday life. They may also experience flashbacks or nightmares about the trauma. Treatment for PTSD typically includes therapy and medication.
Some of the major players in the post-traumatic stress disorder (ptsd) therapeutics market are GlaxoSmithKline, Pfizer, Eli Lilly, H. Lundbeck.
The post-traumatic stress disorder (ptsd) therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
5.2.1 Antidepressants
5.2.2 Anxiolytics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
9.6.1 Antidepressants
9.6.2 Anxiolytics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
10.6.1 Antidepressants
10.6.2 Anxiolytics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
11.6.1 Antidepressants
11.6.2 Anxiolytics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
12.6.1 Antidepressants
12.6.2 Anxiolytics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Post-Traumatic Stress Disorder (PTSD) Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Type
13.6.1 Antidepressants
13.6.2 Anxiolytics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Post-Traumatic Stress Disorder (PTSD) Therapeutics Market: Competitive Dashboard
14.2 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Pfizer
14.3.3 Eli Lilly
14.3.4 H. Lundbeck
